Maja D JESIC, Helena STOCK, Smiljka KOVACEVIC, Marko SAVIC, Milo M JE İ, Vera ZDRAVKOVIC

Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient’s follow-up

Background. Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium channel, often result in neonatal diabetes. Case. In this report, we describe a 10-year-old girl who is heterozygous for a new missense mutation in the KCNJ11 gene and whose treatment was successfully switched from insulin to sulfonylurea (glibenclamide) therapy when she was one month old. 10-year data on a low-dose of glibenclamide monotherapy showed excellent glycaemic control with no reports of severe hypoglycaemia and microvascular complications. Conclusion. An early genetic diagnosis of neonatal diabetes mellitus is highly beneficial because early switch from insulin to sulfonylurea is safe, avoids unnecessary insulin therapy and promotes sustained improvement of glycaemic control on long-term follow-up

PDF

___

1. Sperling MA. ATP-sensitive potassium channels – neonatal diabetes mellitus and beyond. N Engl J Med 2006; 355: 507-510.

2. Aydin BK, Bundak R, Bas F, et al. Permanent neonatal diabetes mellitus: same mutation, different glycaemic control with sulfonylurea therapy on long-term follow up. J Clin Res Pediatr Endocrinol 2012; 4: 107-110.

3. Klupa T, Skupien J, Mirkiewicz-Sieradzka B, et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol Ther 2010; 12: 387-391.

4. Vendramini MF, Gurgel LC, Moises RS. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene. Arq Bras Endocrinol Metabol 2010; 54: 682-684.

5. Iafusco D, Bizzarri C, Cadario F, et al. No beta cell desensitization after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 2011; 54: 2736-2738.

6. Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation. Diabetes Res Clin Pract 2011; 91: e1-e3.

7. Dahl A, Kumar A. Recent advances in neonatal diabetes. Diabetes Metab Syndr Obes 2020; 13: 355- 364.

8. Lemelman MB, Letourneau L, Greely SAW. Neonatal diabetes mellitus: an update on diagnosis and management. Clin Perinatol 2018; 45: 41-59.

9. De Franco E, Ellard S. Genome, exome, and targeted next-generation sequencing in neonatal diabetes. Pediatr Clin North Am 2015; 62: 1037-1053.

10. Hattersley AT, Greeley SAW, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2018; 19(Suppl 27): 47-63.

11. Letourneau LR, Carmody D, Wroblewski K, et al. Diabetes presentation in infancy: high risk of diabetic ketoacidosis. Diabetes Care 2017; 40: e147-e148.

12. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004; 89: 5504-5507.

13. Pearson ER, Flechtner I, Njolstad PR, et al; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir 6.2 mutations. N Engl J Med 2006; 355: 467-477.

14. Li X, Xu A, Sheng H, et al. Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: experience from China. Pediatric Diabetes 2018; 19: 251-258.

15. Bowman P, Sulen A, Barbetii F, et al; Neonatal Diabetes International Collaborative Group. Effectivness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 2018; 6: 637-646.